Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations. Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist. In India, it is also marketed by Vivere Imaging as Viv-butrol. gadobutrol.txt Last modified: 2024/06/07 02:53by 127.0.0.1